Cue Biopharma Inc expected to post a loss of 29 cents a share - Earnings Preview

Cue Biopharma

06/05/2023 03:13

* Cue Biopharma Inc  CUE.OQ   CUE.O  is expected to show a
rise in
quarterly revenue when it reports  results on May 8
(estimated). 
    * The Boston Massachusetts-based  company is expected to
report  a
95.0% increase in revenue to $1.95 million from $1 million a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Cue Biopharma Inc
is for
a loss of 29 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cue
Biopharma Inc
is $9​, above​ its last closing price of $4.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.29       -0.31      -0.38     Missed  -22.6
 Sep. 30 2022  -0.38       -0.38      -0.31     Beat    18.4
 Jun. 30 2022  -0.43       -0.42      -0.37     Beat    12.6​
 Mar. 31 2022  -0.43       -0.43      -0.44     Missed  -2.9
 ​​Dec.        -0.45       -0.38      -0.25     Beat    35.1
 31 2021                                                
 Sep. 30 2021  -0.38       -0.39      -0.41     Missed  -5.1​
 Jun. 30 2021  -0.41       -0.42      -0.33     Beat    20.7
 Mar. 31 2021  -0.38       -0.38      -0.41     Missed  -8.5
 This summary was machine generated May 6 at 02:12 GMT.  All
figures in US dollars  unless otherwise stated